The FDA approved Bosulif for children aged 1 and older with newly diagnosed or resistant/intolerant chronic myelogenous leukemia. The Food and Drug Administration ...
A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...
Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario’s new ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...
Credit: Getty Images. A new capsule dosage form has also been approved in 50mg and 100mg strengths. The Food and Drug Administration (FDA) has approved Bosulif ...
The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...
By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Radich is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback